LAUSR

Big pharma is embracing open-access publishing like never before

Sign Up to like & get
recommendations!
1 Published in 2019 at "Nature"

DOI: 10.1038/d41586-019-00610-2

Abstract: Proportion of open-access publications with authors from the pharmaceutical industry doubled between 2009 and 2016. Proportion of open-access publications with authors from the pharmaceutical industry doubled between 2009 and 2016. read more here.

Keywords: open access; access; pharma embracing; big pharma ... See more keywords

Delivering advanced therapies: the big pharma approach

Sign Up to like & get
recommendations!
0 Published in 2017 at "Gene Therapy"

DOI: 10.1038/gt.2017.65

Abstract: After two decades of focused development and some recent clinical successes, cell and gene therapy (CGT) is emerging as a promising approach to personalized medicines. Genetically engineered cells as a medical modality are poised to… read more here.

Keywords: delivering advanced; big pharma; therapies big; pharma approach ... See more keywords

What you need to know when working with big pharma

Sign Up to like & get
recommendations!
1 Published in 2020 at "Nature Biotechnology"

DOI: 10.1038/s41587-020-0576-2

Abstract: Ask any pharma executive whether their company is interested in academic collaborations and the answer is a resounding “yes.” So why do so few academic institutions have success stories to share? read more here.

Keywords: working big; know working; big pharma; need know ... See more keywords

Nanobiotech in big pharma: a business perspective.

Sign Up to like & get
recommendations!
0 Published in 2017 at "Nanomedicine"

DOI: 10.2217/nnm-2016-0348

Abstract: Since the early 2000s, numerous publications have presented major scientific opportunities that can be achieved through integrating insights from the area of nanotech into biotech (nanobiotech). This paper aims to explore the economic significance that… read more here.

Keywords: big pharma; nanobiotech big; nanobiotech; pharma business ... See more keywords

Screening of Big Pharma’s Library against Various in-house Biological Targets

Sign Up to like & get
recommendations!
1 Published in 2022 at "Molecules"

DOI: 10.3390/molecules27144484

Abstract: Open innovation initiatives provide opportunities for collaboration and sharing of knowledge and experience between industry, academia, and government institutions. Through open innovation, Merck is offering a Mini Library of 80 carefully selected compounds from previous… read more here.

Keywords: house; big pharma; library various; screening big ... See more keywords